Abstract
Margriet J Vervoordeldonk, Caroline J Aalbers & Paul P Tak† †Author for correspondence Academic Medical Center/University of Amsterdam, Division of Clinical Immunology and Rheumatology, F4–218, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands Tel.: +31 205 662 171; Fax: +31 206 919 658; p.p.tak@amc.uva.nl and, Arthrogen BV, Amsterdam, The Netherlands ‘[There is] a strong rationale for IFN-β gene therapy as a novel therapeutic approach for arthritis.’
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
